Neville M E, Lischner H W
J Exp Med. 1981 Dec 1;154(6):1868-80. doi: 10.1084/jem.154.6.1868.
Cells that participate in immune complex-induced production of leukocyte migration inhibitory factor (LIF) activity can be concentrated in a population making up 2-4% of human peripheral blood lymphocytes in which greater than 90% of the cells are active in a single cell antibody-dependent cellular cytotoxicity assay. When so concentrated, such killer (K) cell preparations are as efficient in producing LIF activity as mitogen activated T lymphocytes. Other Fc receptor (FcR)-bearing lymphocytes, including natural killer (NK) cells, do not produce measurable LIF activity when incubated with immune complexes (additional evidence that the K and NK cells among ligands to the FcR of the appropriate lymphocytes, possibly without need for exogenous receptor bridging, is the only requirement for their activation to immune complex-induced lymphokine production (ICLP). It is probable that ICLP by K cells palays a role in antibody-mediated effector functions in vivo.
参与免疫复合物诱导产生白细胞迁移抑制因子(LIF)活性的细胞,可富集于占人外周血淋巴细胞2% - 4%的群体中,其中超过90%的细胞在单细胞抗体依赖性细胞毒性试验中具有活性。如此富集后,这类杀伤(K)细胞制剂在产生LIF活性方面与丝裂原激活的T淋巴细胞一样高效。其他带有Fc受体(FcR)的淋巴细胞,包括自然杀伤(NK)细胞,与免疫复合物一起孵育时不会产生可测量的LIF活性(这是进一步的证据,表明适当淋巴细胞的FcR配体中的K细胞和NK细胞,可能无需外源性受体桥接,是其激活以产生免疫复合物诱导的淋巴因子产生(ICLP)的唯一要求。K细胞的ICLP可能在体内抗体介导的效应功能中起作用。